AzTrials
AzTrials

Healthy NutritionNCT06259825

Omega-3-Index Response to Eating Poultry Foods Naturally Enriched With Omega-3 Polyunsaturated Fatty Acids

A study testing Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs) in people with Healthy Nutrition and Healthy Adults, run by King Abdulaziz University at 1 site in Saudi Arabia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Diets low in seafood omega-3 polyunsaturated fatty acids (PUFAs) are very prevalent. Such diets have recently been ranked as the sixth most important dietary risk factor-1.5 million deaths and 33 million disability-adjusted life-years worldwide are attributable to this deficiency. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Nutrition, Healthy Adults
What is being tested?
Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
1 siteSaudi Arabia
Study dates
1 Feb 2024to Oct 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adults (≥ 18 years and < 70 years)
  • Regular consumers (≥ 4 portions weekly) or willing to be regular consumers of chicken-meat.
  • Regular consumers (≥ 4 eggs weekly) or willing to be regular consumers of eggs.
  • Able to give informed consent.

Who cannot join

  • Concurrent or recent (within last 3 months) regular intake of long-chain omega-3-PUFA supplements (containing EPA, DPA and/or DHA).
  • Previous diagnosis of;
  • significant cardiovascular disease (e.g. myocardial infarction, coronary intervention, or stroke),
  • significant mental ill-health (e.g. major depression, psychosis or dementia) or
  • a haemoglobinopathy such as sickle cell anaemia or thalassemia .
  • Any other serious medical condition that may adversely affect the patient's safety, limit the subject's ability to participate in the study, comply with follow-up requirements or impact the scientific integrity of the study.

Trial locations and contacts

1 site in 1 country.

Alice V Stanton, MB, PhD contact

+353872885480

astanton@rcsi.ie

Salwa Albar, BSc, PhD contact

+966505317160

salbar1@kau.edu.sa

Saudi Arabia1 site, 1 recruiting
  • Department of Food Science and Nutrition, King Abdulaziz University

    Jeddah, 21589

    Salwa A Albar, BSc, PhD, +966505317160, salbar1@kau.edu.sa

    Hala F AL-Marzouki, BSc, MSc, +966504663559, hfalmarzoukii@kau.edu.sa

    Recruiting

Other trials in Saudi Arabia

About this study

Official title: Omega-3-Index Response to Eating Poultry Foods Naturally Enriched With Omega-3 Polyunsaturated Fatty Acids: A Randomized Controlled Trial in Healthy Saudi Adults

Diets low in seafood omega-3 polyunsaturated fatty acids (PUFAs) are very prevalent. Such diets have recently been ranked as the sixth most important dietary risk factor-1.5 million deaths and 33 million disability-adjusted life-years worldwide are attributable to this deficiency. Wild oily fish stocks are insufficient to feed the world's population, and levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in farmed fish have more than halved in the last 20 years.

The primary objective of this randomised, double-blinded, controlled nutritional trial will be to test if consumption of at least 4 servings of omega-3 PUFA-enriched chicken-meat and 4 enriched eggs per week, over a 4-month period, results in measurably higher blood levels of EPA and DHA in healthy Saudi adults.

Read more

This will be a randomised double-blind interventional study. Eighty adult male and female participants (age ≥ 18 years of age) will be asked to eat at least 4 portions of omega-3-PUFA enriched (or control) chicken-meat per week, and at least 4 omega-3-PUFA enriched (or control) eggs per week, for 4 months. Participants will be assessed at baseline and at monthly intervals for 4 months. Assessments at these visits will include; comprehensive lifestyle and medical history; food frequency questionnaire; 3 days food record; height, weight, waist and hip circumferences; blood sampling; participant well-being and adverse events. Measurement of plasma and red blood cell levels of EPA, DHA and Docosapentaenoic acid (DPA) will be performed at baseline and at study end using gas chromatography-mass spectroscopy.

The primary end point will be the change in red blood cell omega-3-index (sum of EPA and DHA expressed as percentage of total fatty acids in erythrocyte membranes) at 4 months. The nutritional trial will be analyzed on an intension to treat basis. Repeated measures ANOVA will be used to compare the two study groups. The study will be reported in accordance with the CONSORT (Consolidated Standards of Reporting Trials) 2010 statement.

Read the detailed description

STUDY RATIONALE

In this randomized, double-blinded, controlled trial, the investigators aim to quantify the impact of regular consumption of omega-3 PUFA enriched chicken-meat and eggs over a four month period, in a healthy Saudi population.

STUDY AIMS AND OBJECTIVES.

The primary objective of this study will be to assess the red blood cell omega-3 index response of healthy Saudi adults to regular consumption of omega-3 PUFA-enriched chicken-meat and eggs. The red blood cell omega-3 index is calculated as the sum of EPA and DHA expressed as a percentage of total fatty acids in erythrocyte (red cell) membranes.

Secondary objectives include;

  • The assessment of red cell and plasma EPA, DPA and DHA responses to regular consumption of omega-3 PUFA-enriched chicken-meat and eggs.
  • The comparison of baseline red cell and plasma levels of EPA, DPA and DHA, amongst Saudi residents who regularly consume oily fish with those that do not regularly consume oily fish, and
  • The assessment of whether the red cell and plasma omega-3 index responses to the omega-3-PUFA enriched foods differs between those that do, and those who do not, include oily fish in their weekly diet.

TRIAL DESIGN.

This will be a randomised double-blind interventional study. The trial will be performed in accordance with the Declaration of Helsinki.

STUDY PARTICIPANTS

80 healthy, community dwelling, participants will be recruited to the study.

RANDOMIZATION AND MASKING

Participants will be randomized to either of two arms;

  • Control / Placebo Intervention: Consumption of at least 4 portions of standard chicken-meat and at least 4 standard eggs per week, for 4 months.
  • Experimental Intervention: Consumption of at least 4 portions of omega-3-PUFA enriched chicken-meat and at least 4 omega-3-PUFA enriched eggs per week, for 4 months.

STUDY CONDUCT

Participants will attend the study center at the screening and baseline visits and at study end (month 4). They will be contacted by telephone at monthly intervals (Months 1, 2 and 3).

At the screening visit, a comprehensive lifestyle and medical history will be taken, a food frequency questionnaire will be completed to capture food intake over the previous year; a 3 days food record will be arranged to capture the current dietary intake of participants; and satisfaction of the inclusion and exclusion criteria will be evaluated.

At the baseline visit, if all inclusion and exclusion criteria are satisfied, participants will be randomized to either the control or the interventional arm of the study.

At both the baseline and month 4 visits, height, weight, waist and hip circumference will be measured, allowing calculation of both the body mass index and the waist-hip ratio. At these two clinic visits fasting blood samples will be taken to allow measurement of plasma and red cell levels of EPA, DPA and DHA, and also to allow storage of plasma aliquots for future research measurements. Participants will be asked to fast, not drink tea or coffee, not smoke and not engage in intense exercise from midnight (minimum 8 hours), prior to the baseline and end-of-study visits. Participants may drink water and take essential medications on these mornings.

At the month 1, 2 and 3 telephone calls, and at the month 4 visit, frequency of consumption of chicken-meat, eggs and fish, during previous week, will be assessed, as will concurrent medications and participant wellbeing.

Participants will be asked to avoid taking long-chain omega-3 PUFA supplements, for the duration of the study.

NUTRITIONAL INTERVENTION

The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland). Omega-3 PUFA enriched chicken (whole chickens, breasts, thighs and drums) and eggs, or the appropriate control chicken and control eggs, will be delivered to the homes of study participants at regular intervals (weekly or two-weekly), so that both they, and up to three additional family members, will be able to eat at least 4 servings per week of chicken meat, and at least 4 eggs weekly over the 4 month study period. The chicken-meat will be delivered frozen, and the eggs will be delivered refrigerated.

MEASUREMENT OF RED CELL AND PLASMA LEVELS OF FATTY ACIDS

Measurement of plasma and red cell levels of EPA, DPA and DHA will be performed at a laboratory with specific expertise in lipid analyses. Total lipids will be extracted from plasma and red cells using a modified Folch method. Phospholipids will be separated from neutral lipids by 1-dimensional thin-layer chromatography. Fatty acid methyl esters will be prepared by direct transesterification and separated using gas chromatography-mass spectrometry allowing quantification of 28 distinct fatty acid peaks. Plasma levels of omega-3-PUFAs will be expressed in microgram/gram, and red cell levels as a percentage of total fatty acids in erythrocyte membranes. The erythrocyte or red cell omega-3 index is calculated as the sum of EPA and DHA expressed as percentage of total fatty acids in erythrocyte membranes.

STATISTICAL ANALYSIS

Analyses and Reporting The study will be analyzed on an intension to treat basis. Standard summary statistics (mean, standard deviation, median, range, %) will be used to describe baseline characteristics of the participants.

Repeated measures ANOVA will be used to compare the 2 study groups. The study will be reported in accordance with the CONSORT (Consolidated Standards of Reporting Trials) 2010 statement.

Sample Size Considerations The primary end point will be the change in red cell omega-3-index at 4 months. In previous studies, the standard deviation of repeated measures of the erythrocyte omega-3 index has been found to be 0.5%. Hence with 80 participants, the study will have in excess of 95% power to detect a difference of 1% in the change from baseline in the omega-3 index between those eating enriched foods versus those eating control foods, at a 2-sided alpha-level of 0.05.

Being tested
Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs), Control poultry foods (chicken-meat and eggs)
Keywords
Omega-3 Polyunsaturated Fatty Acids, Omega-3 PUFAs, Poultry Foods, Chicken-meat, Eggs, Randomized Nutritional Trial

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)Other

    At least four portions of omega-3 PUFA enriched chicken-meat (whole chickens, breasts, thighs and drums) and at least four omega-3 PUFA enriched eggs will be consumed weekly for 4 months. The poultry meat and eggs will be enriched by feeding chickens a complete feed which includes algae, which is a rich source of omega-3 PUFAs (OmegaPro, Humanitiv, Meath, Ireland).

  • Control poultry foods (chicken-meat and eggs)Other

    At least four portions of standard chicken-meat (whole chickens, breasts, thighs and drums) and at least four standard eggs will be consumed weekly for 4 months.

Study groups in NCT06259825
Study groupRoleWhat they receive
Control Chicken-meat and Control EggsPlacebo comparatorConsumption of at least 4 portions of standard chicken-meat and at least 4 standard eggs per week, for 4 months.
Receives: Other: Control poultry foods (chicken-meat and eggs)
Omega-3 Chicken-meat and Omega-3 EggsExperimentalConsumption of at least 4 portions of omega-3-PUFA enriched chicken-meat and at least 4 omega-3-PUFA enriched eggs per week, for 4 months.
Receives: Other: Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in the red cell omega-3 index at 4 months

    The difference between the red cell omega-3 index at baseline and at 4 months. The red blood cell omega-3 index is calculated as the sum of EPA and DHA expressed as a percentage of total fatty acids in erythrocyte (red cell) membranes.

    Measured: 4 months (16 weeks)

Secondary outcomes (6)
  1. Change in red cell EPA

    The difference between red cell levels of eicosapentaenoic acid (EPA) at baseline and at 4 months

    Measured: 4 months (16 weeks)

  2. Change in red cell DPA

    The difference between red cell levels of docosapentaenoic acid (DPA) at baseline and at 4 months

    Measured: 4 months (16 weeks)

  3. Change in red cell DHA

    The difference between red cell levels of docosahexaenoic acid (DHA) at baseline and at 4 months

    Measured: 4 months (16 weeks)

  4. Change in plasma EPA

    The difference between plasma levels of eicosapentaenoic acid (EPA) at baseline and at 4 months

    Measured: 4 months (16 weeks)

  5. Change in plasma DPA

    The difference between plasma levels of docosapentaenoic acid (DPA) at baseline and at 4 months

    Measured: 4 months (16 weeks)

  6. Change in plasma DHA

    The difference between plasma levels of docosahexaenoic acid (DHA) at baseline and at 4 months

    Measured: 4 months (16 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Feb 2024
  2. Study start1 Feb 2024
  3. Primary completionOct 2024 (estimated)
  4. Study completionOct 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
This will be a randomised double-blind interventional study. Participants will be randomized to either of two arms; * Control / Placebo Intervention: Consumption of at least 4 portions of standard chicken-meat and at least 4 standard eggs per week, for 4 months. * Experimental Intervention: Consumption of at least 4 portions of omega-3-PUFA enriched chicken-meat and at least 4 omega-3-PUFA enriched eggs per week, for 4 months.
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06259825
Sponsor's protocol ID
KAU-664-23
Status last verified
Mar 2024
First submitted
7 Feb 2024
Last updated
13 Mar 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All de-identified individual participant data that underlie the results in a published paper, and applicable supporting clinical trial documents, may be available upon request,

Questions about this trial

What is this clinical trial studying?

A study testing Omega-3 polyunsaturated fatty acid, naturally enriched, poultry foods (chicken-meat and eggs) in people with Healthy Nutrition and Healthy Adults, run by King Abdulaziz University at 1 site in Saudi Arabia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Alice V Stanton, MB, PhD (+353872885480, astanton@rcsi.ie), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in the red cell omega-3 index at 4 months (time frame: 4 months (16 weeks)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in